보고서 요약(국문)

시장 개요
전 세계 중추신경계 바이오마커 시장 규모는 2022년 47억 9,080만 달러에 달했으며, 2030년까지 98억 5,270만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 이 시장은 예측 기간(2023~2030년) 동안 연평균 9.7%의 성장률을 기록할 것으로 예상됩니다.
바이오마커 또는 생물학적 지표는 생물학적 과정, 질병 상태 또는 치료 반응에 대한 정보를 제공하는 정량적 측정값입니다. 바이오마커는 특정 질환의 원인과 병태생리를 더 잘 이해할 수 있도록 도와주며, 연구자와 임상의에게 다양한 질환 및 장애에 대한 진단, 치료 및 예후에 대한 귀중한 통찰력을 제공할 수 있는 잠재력을 가지고 있습니다.
중추신경계 바이오마커 시장은 중추신경계 조직, 뇌척수액 또는 혈액에 대한 단백질체학, 유전체학 및 대사체학 분석과 영상 기술의 결합, 그리고 새로운 바이오마커 개발과 같은 요인에 의해 주도되고 있습니다.

시장 동향
새로운 바이오마커에 대한 수요 증가
중추신경계 질환의 잠재적 신규 바이오마커로는 타우 단백질, 신경섬유 경쇄(NFL), 신경교 섬유성 산성 단백질(GFAP), 유비퀴틴 C-말단 가수분해효소-L1(UCH-L1) 등이 있습니다. 타우 단백질은 중추신경계 백질에 주로 존재하는 신경축삭 표지자로, 허혈성 뇌졸중과 심정지에서 증가하는 것으로 보고되었습니다. NFL은 심정지 후 예후 예측에 매우 정확하지만, 알츠하이머병과 같은 신경퇴행성 질환에서도 증가하는 것으로 알려져 있습니다.
GFAP는 신경 보호 기전의 일부로 생성되는 성상세포 표지자로, 두부 외상, 뇌출혈, 허혈성 뇌졸중, 심정지 후 예후와 관련이 있습니다. UCH-L1은 신경축삭 안정성과 뇌 손상 후 복구에 중요한 신경 세포체 표지자입니다.

기술 발전으로 바이오마커 발견 속도가 빨라졌지만, 대부분은 아직 검증되지 않았습니다. 임상 시험 및 진료에 바이오마커를 통합하면 연구 효율성을 높이고 맞춤형 신경학 발전에 도움이 될 것입니다.
중추신경계 바이오마커 검사 및 진단 비용의 높은 부담
샘플 수집 및 보관과 같은 검증 과정의 높은 비용으로 인해, 표준 치료법으로 간주되지 않는 바이오마커 기반 치료법에 대한 보험 적용이 제한되면서 정부 규정 및 정책이 변화하고 있습니다.
바이오마커가 검사에 상당한 가치를 더함에도 불구하고, 환급액은 제한적입니다. 예를 들어, 5천만 명 이상의 수혜자를 보유한 미국 최대 의료보험 기관인 메디케어는 실험 의약품이나 대부분의 선별 검사 및 바이오마커 검사에 대한 비용을 지원하지 않습니다. 따라서 위의 요인들은 예측 기간 동안 시장 성장을 저해할 것으로 예상됩니다.
코로나19 영향 분석
코로나19 팬데믹은 인지 장애 및 신경 퇴행성 변화를 포함한 다양한 신경학적 합병증과 관련이 있습니다. 예를 들어, 웨스트버지니아주 마셜 대학교는 COVID-19와 관련된 다양한 신경퇴행성 변화를 검토하고 질병 진행 및 중증도와 관련된 주요 순환 바이오마커의 중요성을 강조했습니다.
문헌 조사 결과, GFAP, NfL, pT181-tau와 같은 중요한 중추신경계 단백질과 다양한 염증성 사이토카인이 COVID-19 환자에서 유의미하게 변화하는 것으로 나타났습니다. COVID-19와 관련된 신경병리학적 변화에 대한 현재의 이해와 질병의 중증화 위험이 있는 환자를 식별하는 데 바이오마커를 활용할 가능성은 아직 제한적입니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁이 전 세계 과학계에 미치는 장기적인 영향과 전쟁 기간 동안 우크라이나의 학계, 의학계, 과학계에서 놓친 연구 기회에 대한 위험성을 분석했습니다. FDA의 임상시험 데이터베이스에 따르면 우크라이나는 251개의 의약품과 의료기기를 시험하고 있었습니다.

임상시험 데이터베이스에 따르면, 2022년 우크라이나에서는 1,000건 이상의 의약품 임상시험이 진행 중이거나 계획되었으며, 그중 786건은 종양학 분야였습니다. 전쟁은 러시아의 임상시험 현장에 부정적인 영향을 미쳐 자원과 인력이 우선순위에 따라 배분되지 못하면서 중추신경계 치료가 악화되었습니다.
세분 분석
글로벌 중추신경계 바이오마커 시장은 유형, 적용 분야, 질병, 최종 사용자 및 지역별로 세분화됩니다.
유형별로는 안전성 바이오마커 부문이 시장 성장을 주도할 것으로 예상됩니다.
안전성 바이오마커 부문은 2022년 중추신경계 바이오마커 시장에서 약 35.5%의 점유율을 차지하며 가장 높은 시장 점유율을 기록했습니다. 우울증, 파킨슨병, 다발성 경화증과 같은 건강 문제에 대한 인식이 높아짐에 따라 안전성 바이오마커가 시장 성장을 주도할 것으로 예상됩니다. 안전성 바이오마커는 전임상 및 임상 연구에서 중요한 역할을 하며, 성장 측정, 계산 및 분석의 급속한 발전으로 인해 중개 연구 분야가 폭발적으로 성장하고 있습니다. 예를 들어, 도나네맙(Donanemab)은 초기 알츠하이머병 환자의 인지 기능과 일상생활 수행 능력을 76주 만에 개선했습니다.
지역 분석
중추신경계 암 발병률 증가 및 연구 개발 투자 확대
북미 지역은 중추신경계 암 발병률 증가와 연구 개발 투자 확대로 인해 예측 기간 동안 전체 시장 점유율의 약 42.7%를 차지할 것으로 예상됩니다. 미국 암 협회(American Cancer Society)에 따르면 뇌종양은 소아 및 청소년에게 두 번째로 흔한 암이며, 중추신경계 바이오마커가 흔히 사용됩니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Acumen Pharmaceuticals, Biogen, Alseres Pharmaceuticals, Aposense, Avacta Life Sciences Ltd., Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, Thermo Fisher Scientific 등이 있습니다.
보고서 구매 이유

• 유형, 적용 분야, 질병, 최종 사용자 및 지역별 글로벌 중추신경계 바이오마커 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 중추신경계 바이오마커 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 중추신경계 바이오마커 시장 보고서는 약 54개의 표, 46개의 그림, 195페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Central Nervous System Biomarkers Market size reached US$ 4,790.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 9,852.7 million by 2030. The market is exhibiting at a CAGR of 9.7% during the forecast period (2023-2030).
Biomarkers or biological markers are quantitative measurements that provide information about biological processes, a disease state, or a response to treatment. They have the potential to better understand the etiology and pathogenesis of a given disorder, providing researchers and clinicians with valuable insight into diagnosis, treatment, and prognosis for many debilitating disorders and diseases.
The central nervous system biomarkers market is driven by factors such as combining proteomics, genomics, and metabolomic interrogation of CNS tissues, CSF, or blood, and imaging technologies and the development of novel biomarkers.
Market Dynamics
Increasing Demand For Novel Biomarkers
Novel potential biomarkers for CNS disorders include the tau protein, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1). The tau protein is a neuroaxonal marker located mainly in the white matter of the central nervous system and is reported to be increased in ischemic stroke and cardiac arrest. The NFL is highly accurate in prognostication after cardiac arrest, but it has also been reported to increase in neurodegenerative disorders such as Alzheimer's disease.
GFAP is an astrocytic marker that is produced as part of a neuroprotective mechanism and has been associated with prognosis after head trauma, intracerebral hemorrhage, ischemic stroke, and cardiac arrest. UCH-L1 is a neuronal cell body marker that is crucial for neuroaxonal stability and repair after brain injury.
Technological advances have increased the pace of biomarker discovery, but most are yet to be validated. Incorporating biomarkers into clinical trials and practice will help improve study efficiency and inform advancements in personalized neurology.
High Cost of CNS Biomarker Testing and Diagnostics
With the high cost of the validation process, such as sample collection & storage, government rules and policies are changing since reimbursements do not cover biomarker-mediated therapies that are not considered standard of care.
Even though biomarkers add significant value to tests, refunds are limited. For instance, Medicare, the nation's largest healthcare insurer with more than 50 million beneficiaries, does not fund experimental medicines or most screening and biomarker tests. Therefore, the above factors are expected to hamper the market growth over the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic has been linked to a range of neurological complications, including cognitive impairment and neurodegenerative changes. For instance, Marshall University, West Virginia, reviewed the diverse neurodegenerative changes associated with COVID-19 and highlighted the importance of major circulating biomarkers, associated with disease progression and severity.
Their literature survey indicated that important CNS proteins, such as GFAP, NfL, and pT181-tau, and various inflammatory cytokines, are altered significantly in COVID-19 patients. The current understanding of the neuropathological changes associated with COVID-19 and the potential use of biomarkers in identifying patients at risk for developing severe forms of the disease is limited.
Russia-Ukraine Conflict Analysis
Risk about the war's long-term impact on the scientific community worldwide and the missed opportunities for research in Ukraine's academic, medical, and scientific disciplines during Russia Ukraine war. Ukraine was testing 251 medicines and devices, according to the FDA's clinical trials database.
According to the clinical trials database, in 2022, over 1,000 medication clinical trials were underway or planned in Ukraine, including 786 in the field of oncology alone. The war has had a negative impact on Russian clinical trial sites, as resources and manpower are not allocated according to priority, leading to worsening CNS care.
Segment Analysis
The global central nervous system biomarkers market is segmented by type, application, disease, end-user, and by region
Based on Type, Safety Biomarkers Segment Is Expected To Drive The Market Growth
The safety biomarkers segment accounted for the highest market stake accounting for approximately 35.5% of the central nervous system biomarkers market in 2022. Safety biomarkers are expected to dominate the market growth due to increased awareness of health issues such as depression, Parkinson's, and multiple sclerosis. They play a crucial role in preclinical and clinical research trials, with rapid changes in growth measurement, computation, and analysis leading to the explosive growth of the translational research field. For Instance, Donanemab improved cognition and ability to perform activities of daily living in patients with early Alzheimer's disease at 76 weeks.
Geographical Analysis
The Rising CNS Cancer Cases And Increasing R&D Expenditure
North America is estimated to hold around 42.7% of the total market share throughout the forecast period due to rising CNS cancer cases and increased R&D expenditure. According to the American Cancer Society, brain malignancy is the second most common cancer in children and adolescents, where CNS biomarkers are commonly used.
Competitive Landscape
The major global players in the market include Acumen Pharmaceuticals, Biogen, Alseres Pharmaceuticals, Aposense, Avacta Life Sciences Ltd., Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, and Thermo Fisher Scientific.
Why Purchase the Report?
• To visualize the global central nervous system biomarkers market segmentation based on type, application, disease, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of central nervous system biomarkers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global central nervous system biomarkers market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Disease
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing demand for Novel Biomarkers
4.1.2. Restraints
4.1.2.1. High Cost of CNS Biomarker Testing and Diagnostics
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Safety Biomarkers*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Efficacy Biomarkers
7.4. Validation Biomarkers
7.5. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Drug Discovery & Development*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Personalized Medicines
8.4. Disease Risk Assessment
8.5. Diagnostics
8.6. Others
9. By Disease
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
9.1.2. Market Attractiveness Index, By Disease
9.2. Multiple Sclerosis*
9.3. Alzheimer's Disease
9.4. Parkinson's Disease
9.5. Traumatic Brain Injury
9.6. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Diagnostic Labs
10.3. Clinics
10.4. Hospitals
10.5. Research Centers
10.6. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8. China
11.5.9. India
11.5.10. Japan
11.5.11. Australia
11.5.12. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Acumen Pharmaceuticals Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Biogen Inc.
13.3. Alseres Pharmaceuticals Inc.
13.4. Aposense Ltd.
13.5. Avacta Life Sciences Ltd.
13.6. Banyan Biomarkers Inc.
13.7. Bio-Rad Laboratories Inc.
13.8. DiaGenic ASA
13.9. G-Biosciences
13.10. Thermo Fisher Scientific Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Acumen Pharmaceuticals Inc., 4.	Key Developments, Biogen Inc., Alseres Pharmaceuticals Inc., Aposense Ltd., Avacta Life Sciences Ltd., Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, Thermo Fisher Scientific Inc.

표 목록 (Tables)

List of Tables Table 1 Global Central Nervous System (CNS) Biomarkers Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Central Nervous System (CNS) Biomarkers Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Central Nervous System (CNS) Biomarkers Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Central Nervous System (CNS) Biomarkers Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Central Nervous System (CNS) Biomarkers Market Value, By Type, 2022-2033 (US$ Billion)

Table 8 Global Central Nervous System (CNS) Biomarkers Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Central Nervous System (CNS) Biomarkers Market Value, By Application, 2022-2033 (US$ Billion)

Table 10 Global Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2025, 2029 & 2033 (US$ Billion)

Table 11 Global Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2022-2033 (US$ Billion)

Table 12 Global Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 13 Global Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2022-2033 (US$ Billion)

Table 14 Global Central Nervous System (CNS) Biomarkers Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 15 Global Central Nervous System (CNS) Biomarkers Market Value, By Region, 2022-2033 (US$ Billion)

Table 16 North America Central Nervous System (CNS) Biomarkers Market Value, By Type, 2022-2033 (US$ Billion)

Table 17 North America Central Nervous System (CNS) Biomarkers Market Value, By Application, 2022-2033 (US$ Billion)

Table 18 North America Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2022-2033 (US$ Billion)

Table 19 North America Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2022-2033 (US$ Billion)

Table 20 North America Central Nervous System (CNS) Biomarkers Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Value, By Type, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Value, By Application, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2022-2033 (US$ Billion)

Table 25 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Value, By Country, 2022-2033 (US$ Billion)

Table 26 Europe Central Nervous System (CNS) Biomarkers Market Value, By Type, 2022-2033 (US$ Billion)

Table 27 Europe Central Nervous System (CNS) Biomarkers Market Value, By Application, 2022-2033 (US$ Billion)

Table 28 Europe Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2022-2033 (US$ Billion)

Table 29 Europe Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2022-2033 (US$ Billion)

Table 30 Europe Central Nervous System (CNS) Biomarkers Market Value, By Country, 2022-2033 (US$ Billion)

Table 31 South America Central Nervous System (CNS) Biomarkers Market Value, By Type, 2022-2033 (US$ Billion)

Table 32 South America Central Nervous System (CNS) Biomarkers Market Value, By Application, 2022-2033 (US$ Billion)

Table 33 South America Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2022-2033 (US$ Billion)

Table 34 South America Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2022-2033 (US$ Billion)

Table 35 South America Central Nervous System (CNS) Biomarkers Market Value, By Country, 2022-2033 (US$ Billion)

Table 36 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Value, By Type, 2022-2033 (US$ Billion)

Table 37 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Value, By Application, 2022-2033 (US$ Billion)

Table 38 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Value, By Disease, 2022-2033 (US$ Billion)

Table 39 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Value, By End-User, 2022-2033 (US$ Billion)

Table 40 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Value, By Country, 2022-2033 (US$ Billion)

Table 41 Quanterix: Overview

Table 42 Quanterix: Product Portfolio

Table 43 Quanterix: Key Developments

Table 44 Alamar Biosciences, Inc.: Overview

Table 45 Alamar Biosciences, Inc.: Product Portfolio

Table 46 Alamar Biosciences, Inc.: Key Developments

Table 47 Thermo Fisher Scientific Inc.: Overview

Table 48 Thermo Fisher Scientific Inc.: Product Portfolio

Table 49 Thermo Fisher Scientific Inc.: Key Developments

Table 50 F. Hoffmann-La Roche Ltd: Overview

Table 51 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 52 F. Hoffmann-La Roche Ltd: Key Developments

Table 53 Siemens Healthineers AG: Overview

Table 54 Siemens Healthineers AG: Product Portfolio

Table 55 Siemens Healthineers AG: Key Developments

Table 56 Sysmex Corporation: Overview

Table 57 Sysmex Corporation: Product Portfolio

Table 58 Sysmex Corporation: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Central Nervous System (CNS) Biomarkers Market Share, By Type, 2024 & 2033 (%)

Figure 3 Global Central Nervous System (CNS) Biomarkers Market Share, By Application, 2024 & 2033 (%)

Figure 4 Global Central Nervous System (CNS) Biomarkers Market Share, By Disease, 2024 & 2033 (%)

Figure 5 Global Central Nervous System (CNS) Biomarkers Market Share, By End-User, 2024 & 2033 (%)

Figure 6 Global Central Nervous System (CNS) Biomarkers Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Central Nervous System (CNS) Biomarkers Market Y-o-Y Growth, By Type, 2023-2033 (%)

Figure 8 Assays Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 9 Kits Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 10 Reagents Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 11 Others Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 12 Global Central Nervous System (CNS) Biomarkers Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 13 Drug Discovery & Development Application in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 14 Disease Risk Assessment Application in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 15 Diagnostics Application in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 16 Others Application in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 17 Global Central Nervous System (CNS) Biomarkers Market Y-o-Y Growth, By Disease, 2023-2033 (%)

Figure 18 Multiple Sclerosis Disease in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 19 Alzheimer's Disease Disease in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 20 Parkinson's Disease Disease in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 21 Traumatic Brain Injury Disease in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 22 Others Disease in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 23 Global Central Nervous System (CNS) Biomarkers Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 24 Diagnostic Labs End-User in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 25 Clinics End-User in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 26 Hospitals End-User in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 27 Research Centers End-User in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 28 Others End-User in Global Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 29 Global Central Nervous System (CNS) Biomarkers Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 30 North America Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 31 North America Central Nervous System (CNS) Biomarkers Market Share, By Type, 2024 & 2033 (%)

Figure 32 North America Central Nervous System (CNS) Biomarkers Market Share, By Application, 2024 & 2033 (%)

Figure 33 North America Central Nervous System (CNS) Biomarkers Market Share, By Disease, 2024 & 2033 (%)

Figure 34 North America Central Nervous System (CNS) Biomarkers Market Share, By End-User, 2024 & 2033 (%)

Figure 35 North America Central Nervous System (CNS) Biomarkers Market Share, By Country, 2024 & 2033 (%)

Figure 36 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 37 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Share, By Type, 2024 & 2033 (%)

Figure 38 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Share, By Application, 2024 & 2033 (%)

Figure 39 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Share, By Disease, 2024 & 2033 (%)

Figure 40 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Share, By End-User, 2024 & 2033 (%)

Figure 41 Asia-Pacific Central Nervous System (CNS) Biomarkers Market Share, By Country, 2024 & 2033 (%)

Figure 42 Europe Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 43 Europe Central Nervous System (CNS) Biomarkers Market Share, By Type, 2024 & 2033 (%)

Figure 44 Europe Central Nervous System (CNS) Biomarkers Market Share, By Application, 2024 & 2033 (%)

Figure 45 Europe Central Nervous System (CNS) Biomarkers Market Share, By Disease, 2024 & 2033 (%)

Figure 46 Europe Central Nervous System (CNS) Biomarkers Market Share, By End-User, 2024 & 2033 (%)

Figure 47 Europe Central Nervous System (CNS) Biomarkers Market Share, By Country, 2024 & 2033 (%)

Figure 48 South America Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 49 South America Central Nervous System (CNS) Biomarkers Market Share, By Type, 2024 & 2033 (%)

Figure 50 South America Central Nervous System (CNS) Biomarkers Market Share, By Application, 2024 & 2033 (%)

Figure 51 South America Central Nervous System (CNS) Biomarkers Market Share, By Disease, 2024 & 2033 (%)

Figure 52 South America Central Nervous System (CNS) Biomarkers Market Share, By End-User, 2024 & 2033 (%)

Figure 53 South America Central Nervous System (CNS) Biomarkers Market Share, By Country, 2024 & 2033 (%)

Figure 54 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Value, 2022-2033 (US$ Billion)

Figure 55 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Share, By Type, 2024 & 2033 (%)

Figure 56 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Share, By Application, 2024 & 2033 (%)

Figure 57 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Share, By Disease, 2024 & 2033 (%)

Figure 58 Middle East and Africa Central Nervous System (CNS) Biomarkers Market Share, By End-User, 2024 & 2033 (%)

Figure 59 Quanterix: Financials

Figure 60 Alamar Biosciences, Inc.: Financials

Figure 61 Thermo Fisher Scientific Inc.: Financials

Figure 62 F. Hoffmann-La Roche Ltd: Financials

Figure 63 Siemens Healthineers AG: Financials

Figure 64 Sysmex Corporation: Financials

글로벌 중추신경계 바이오마커 시장 – 2023-2030

Global Central Nervous System Biomarkers Market - 2023-2030